ViroPharma Incorporated has released their third quarter financial results. The main takeaways are as follow:
- Achieved a record $118 million in net product sales;
- Increased Cinryze net sales by 69 percent over prior year’s third quarter to $49 million;
- Attained Non-GAAP adjusted net income of $47 million, representing 70 percent growth over the prior year third quarter; GAAP net income reached $38 million;
- Delivered positive cash flows from operations of $45 million;
- Improved working capital to $512 million as of September 30, 2010, including cash, cash equivalents and short-term investments of $448 million; and
- Presented data from Phase 1 study of VP20621 (non-toxigenic C. difficile) at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
You can read the entire news from ViroPhrama’s website.
